| Arnold Barry Calica, MD | |
|
525 N 18th St Ste 407, Phoenix, AZ 85006-3746 | |
| (602) 253-5453 | |
| (602) 253-5997 |
| Full Name | Arnold Barry Calica |
|---|---|
| Gender | Male |
| Speciality | Neurological Surgery |
| Location | 525 N 18th St Ste 407, Phoenix, Arizona |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1215905401 | NPI | - | NPPES |
| 278764 | Medicaid | AZ |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207T00000X | Neurological Surgery | 12548 (Arizona) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Arnold Barry Calica, MD 525 N 18th St Ste 407, Phoenix, AZ 85006-3746 Ph: (602) 253-5453 | Arnold Barry Calica, MD 525 N 18th St Ste 407, Phoenix, AZ 85006-3746 Ph: (602) 253-5453 |
News Archive
Fertility problems, recurrent miscarriages, and pregnancy complications can occur when maternal immunological tolerance of the fetus is impaired. G-rard Chaouat and colleagues from Inserm et Assistance Publique et Universit- Paris Sud Orsay, Hopital Antoine B-cl-re, Clamart Cedex, France, trace the evolution of the science of reproductive immunology to show how the current understanding of maternal-fetal tolerance/dialogue has developed, and its implications for the treatment of infertility disorders
In a move that some fear could compromise care for Medicare recipients, the Obama administration is proposing to remove special protections that guarantee seniors access to a wide selection of three types of drugs.
A new treatment developed and tested by University of Oklahoma researchers not only killed large breast cancer tumors, but reduced the need for mastectomies by almost 90 percent. The latest results appear in an upcoming issue of the Annals of Surgical Oncology.
AVANIR Pharmaceuticals, Inc. (NASDAQ:AVNR) today announced additional detailed results from the confirmatory double-blind Phase III STAR trial evaluating two doses of the investigational drug Zenvia™ (dextromethorphan/quinidine) compared to placebo in the treatment of pseudobulbar affect (PBA) among patients with underlying multiple sclerosis (MS) or amyotrophic lateral sclerosis (ALS). Over the course of the 12-week study in the MS patient subset, Zenvia 30/10 mg met the primary efficacy endpoint by reducing PBA episode rates by an incremental 11.9% beyond placebo
› Verified 3 days ago
Curtis A Dickman, MD Neurological Surgery Medicare: Not Enrolled in Medicare Practice Location: 2910 N 3rd Ave, Phoenix, AZ 85013 Phone: 602-406-3632 Fax: 602-406-4187 | |
Dr. Naresh P Patel, M.D. Neurological Surgery Medicare: Accepting Medicare Assignments Practice Location: 5777 E Mayo Blvd, Phoenix, AZ 85054 Phone: 480-301-8000 | |
James Zhou, Neurological Surgery Medicare: Not Enrolled in Medicare Practice Location: 350 W Thomas Rd, Phoenix, AZ 85013 Phone: 602-406-4958 | |
Dr. Mark Edward Oppenlander, MD Neurological Surgery Medicare: Accepting Medicare Assignments Practice Location: 19636 N 27th Ave Ste 203, Phoenix, AZ 85027 Phone: 235-625-0506 Fax: 623-562-5051 | |
Dr. Erik I Curtis, M.D., M.S. Neurological Surgery Medicare: Accepting Medicare Assignments Practice Location: 2222 E Highland Ave Ste 222, Phoenix, AZ 85016 Phone: 602-603-0971 | |
Dr. Michael T Lawton, MD Neurological Surgery Medicare: Accepting Medicare Assignments Practice Location: 2910 N 3rd Ave, Phoenix, AZ 85013 Phone: 602-406-3489 Fax: 602-406-4402 | |
Dr. Jonathan Seth Hott, MD Neurological Surgery Medicare: Medicare Enrolled Practice Location: 9225 N 3rd St, Suite 100, Phoenix, AZ 85020 Phone: 602-943-4509 Fax: 602-943-0348 |